Klimadynon® in Comparison to Conjugated Oestrogens in Women Suffering From Menopausal Complaints

Inclusion Criteria: * Only postmenopausal (amenorrhea for 6 months at least) women may be enrolled in the study * Women after ovariectomy may also be enrolled if surgery was carried out at least 6 months prior to the enrollment. Only women between the age of 40 and 60 may be included * 2 weeks (control -1, week -2, day -14) before the beginning of the treatment the following hormone values must have been analyzed: * estradiol-17ß ≤ 0.15 nmol/l corresponding to ≤ 40 pg/ml and follicle stimulating hormone (FSH) ≥ 25 milliunits per milliliter (mU/ml) * These hormone analyses must be carried out at the competent local laboratory * In addition to other menopausal complaints the women must have hot flushes / outbreaks of sweating: * Diary: During the "run-in period" daily ≥ 3 hot flushes / outbreaks of sweating * Modified Menopause Rating Scale, 1st item twofold (week -2 and 0) ≥ 0.3 * A sum score taken twice from the modified (only items 1 - 6) Menopause Rating Scale within 2 weeks (week - 1 and 0) before the beginning of treatment must be ≥ 1.7 * In case of a pretreatment with estrogen a wash-out phase of 6 weeks is necessary in case of oral or transdermal administration. After the 4th week of wash-out the patient may be included in the "run-in period" Exclusion Criteria: * General criteria for exclusion: * Non-responder (= no therapeutic success) under a pretreatment with estrogen * Amenorrhea for \< 6 months * In case of an estrogen pretreatment last menstruation (menopause) \> 3 years earlier * Sum score of the modified Menopause Rating Scale (items 1 - 6) during the "run-in period" twice (week -2 and 0) \< 1.7 * No hot flushes / outbreaks of sweating (see Inclusion criteria) * At one of the appointments of the "run-in period" (week -2 and 0) more than one question of items 1 - 6 of the modified Menopause Rating Scale (MMRS) not answered * During the "run-in period" at the appointment week -2: estradiol-17ß \> 40 pg/ml corresponding to \> 0.15 nmol/l and FSH \< 25 mU/ml * Condition after hysterectomy * Simultaneous ingestion of estrogen-containing products in addition to the test products * Any addition ingestion of psychotropic drugs, antidepressants and sleeping aids (hypnotics / sedatives) * Treatment with another study drug in the 2 months preceding the beginning of the study * Considerable overweight (exceeding the target body weight \[height in cm minus 100\] by more than 30%) * Poor general condition * Alcohol or drug abuse * Poor compliance * Exclusion criteria based on conjugated estrogens or medroxyprogesterone: * Any contraindication for estrogen * Unresolved genital bleeding * Suspicion / existence of estrogen-dependent mammary carcinoma (mammography and/or endometrial carcinoma) * Endometriosis * Endometrial hyperplasia (including hyperplastic polypoid endometrium, which has not yet reached the stage of a glandular cystic hyperplasia) * Thickness of endometrium \> 5 mm * Existing thromboembolism or thromboembolism in the past * Phlebitis in the past 2 years or actually existing * Acute or chronic hepatic lesion (aspartate transaminase and/or alanine transaminase and/or gamma glutamyl transferase twice the normal range) * Metabolic disorders of bile pigments (Dubin-Johnson's syndrome, Rotor syndrome, pregnancy icterus with/without pruritus in previous pregnancy) * Sickle cell anemia * Clinically relevant hypertriglyceridemia or hypercholesterolemia * Heart attack in the past * Severe varicosis * Known sensitivity to medroxyprogesterone * Case history of anaphylactic reaction * Any neoplasm at the genitals * Case history of antidepressant treatment * Diabetes mellitus with or without treatment